Get the Stockscreener App
195.27
1.80%
3.3212
Biogen Inc stock is traded at $195.27, with a volume of 669.13K.
It is up +1.80% in the last 24 hours and down -1.63% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$191.95
Open:
$191.21
24h Volume:
669.13K
Relative Volume:
0.54
Market Cap:
$28.81B
Revenue:
$9.60B
Net Income/Loss:
$1.37B
P/E Ratio:
20.96
EPS:
9.3182
Net Cash Flow:
$2.32B
1W Performance:
-2.48%
1M Performance:
-1.63%
6M Performance:
+15.92%
1Y Performance:
+53.26%
1-Day Range:
$186.03
$196.11
1-Week Range:
$186.03
$210.87
52-Week Range:
$121.05
$219.72
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
195.17 | 30.86B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,148.09 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
251.30 | 620.51B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
247.44 | 438.16B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.50 | 306.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.34 | 292.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Upgrade | UBS | Neutral → Buy |
| Apr-20-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen stock holds steady as Alzheimer portfolio and pipeline shape the long-term story - Ad-hoc-news.de
Biogen Inc (BIIB) Shares Fall 8.2% -- What GF Score of 74 Tells Investors - GuruFocus
Biogen Inc.'s Stock Price Plummets to $191.95, Recording a Sharp 8.17% DropThe Latest Market Update - Smartkarma
Biogen (BIIB) Alzheimer’s Association International Conference (AAIC Meeting) 2026 summary - Quartr
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss - Yahoo Finance
BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study - TradingView
Biogen at aaic 2026: tau drug advances despite mixed trial readout - Investing.com
Biogen (BIIB) Reports Mixed Results on Alzheimer's Drug Diraners - GuruFocus
Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi - Yahoo! Finance Canada
Biogen Inc at Alzheimer's Association International Conference (AAIC) Transcript - GuruFocus
Why Is Biogen Stock Falling Tuesday? - Benzinga
Eisai, Biogen report real-world Alzheimer’s drug study results - Investing.com
Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradox - Investing.com South Africa
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment - Biogen
Biogen drops after data for novel Alzheimer’s drug (BIIB:NASDAQ) - Seeking Alpha
Italy The AGCM Opens a Formal Investigation into Biogen for Alleged Abuse of Dominant Position in th - Bird & Bird
Biogen slides as investors reassess Alzheimer’s data and earnings overhang - Quiver Quantitative
Biogen Drops 7.7% After Morgan Stanley Maintains Equal-Weight - AlphaStreet
Biogen Shares Fall as Alzheimer’s Tau Trial Data Disappoint - Bloomberg.com
Biogen drops after additional mid-stage trial data for Ionis-partnered Alzheimer’s drug - Seeking Alpha
Biogen Shares Rise After Positive Phase 2 Alzheimer’s Trial Results (BIIB) - Yahoo Finance
Biogen reports phase 2 Alzheimer’s drug trial results - Investing.com
Biogen reports phase 2 Alzheimer’s drug trial results By Investing.com - Investing.com Canada
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease - Biogen
Biogen stock rises on positive Alzheimer’s drug trial data - Investing.com
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed - marketscreener.com
Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows - STAT
Biogen’s Diranersen Efficacy Similar To Leqembi On Key Alzheimer’s Endpoint - insights.citeline.com
Piper Sandler reiterates Biogen stock rating on Alzheimer’s drugs - Investing.com
Piper Sandler reiterates Biogen stock rating on Alzheimer’s drugs By Investing.com - Investing.com Canada
Eisai, Biogen Push Full SC Leqembi With FDA Nod As Alzheimer’s Market Competition Builds - insights.citeline.com
Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector? - simplywall.st
Biogen (BIIB) Receives Buy Rating with $255 Target Following Leq - GuruFocus
Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Tr - GuruFocus
A Look at Biogen Inc (BIIB) After 5.0% Gain -- GF Value $191.79 vs Price $209.03 - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MSN
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease - Biogen
Biogen Inc.’s stock price soars to $209.03, marking a bullish 4.96% surge - Smartkarma
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug - Reuters
Biogen (BIIB) Upgraded to Buy with Price Target Raised to $235 - GuruFocus
Biogen (BIIB) Sees Boost Following Early FDA Approval of Leqembi - GuruFocus
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details - Barron's
This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth… - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: Navigating a Robust Pipeline with 11.89% Upside Potential - DirectorsTalk Interviews
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026 - Biogen
Eisai and Biogen Present AAIC 2026 Data Supporting Comparable Efficacy and Safety of LEQEMBI Subcutaneous Autoinjector and IV Dosing in Early Alzheimer’s Disease - Quiver Quantitative
Eisai Co., Ltd. And Biogen Inc. Present Clinical Data Supporting Leqembi Subcutaneous Autoinjector Efficacy And Safety Comparable To Intravenous Formulation In Early Alzheimer's Disease - marketscreener.com
Biogen stock reflects Alzheimer portfolio repositioning as neurology pipeline gains weight - ad-hoc-news.de
AstraZeneca's $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw - finance.biggo.com
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):